Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue...
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as...
GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in...
Hosted by Arizona State University and Mayo ClinicAnivive provides $50,000 in travel awardsLeading global experts pioneering novel fungal vaccines, therapeutics...
CHICAGO, Feb. 27, 2025 /PRNewswire/ -- BlackDoctor.org (BDO), a nationally recognized leader in Black health, announces finalists of its 10th...
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader...
HOUSTON, Feb. 26, 2025 /PRNewswire/ -- Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical...
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to...
Their first co-developed product, Alveo Sense™ Poultry Avian Influenza was introduced in the EU in late 2024 and is now...
Global Health Leader Howard Zucker Teams With HANG Media to Invite the Audience Onto The Show NEW YORK, Feb....
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE...
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support...
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Exploring new opportunities within the fast-growing market of microfluidics BORDEAUX, France, Feb. 20, 2025 /PRNewswire/ -- Syensqo, a leading specialty...
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...